• Announced Nasal Nalmefene program with positive Phase 1 data for OPNT003, a long-acting opioid antagonist for opioid overdose
  • Entered manufacturing agreement with Consort Medical for OPNT003
  • Received funding from the NIH and BARDA to fuel OPNT003 research & development activities
  • Awarded grant from Walter Reed to develop OPNT005, a heroin vaccine for OUD
  • Expanded into acute cannabinoid overdose (ACO) through an exclusive global licensing agreement with Sanofi for OPNT004, drinabant
  • Discontinued OPNT001 program evaluating naloxone in the treatment of Bulimia Nervosa
  • Published clinical data in support of OPNT002, nasal naltrexone, for on-demand treatment of alcohol use disorder (AUD)
  • Widened partnership with Sanofi through manufacturing agreement for OPNT004